Related Experiment Videos

Interleukin-1 receptor antagonist gene VNTR polymorphism is associated with coronary artery disease

Ahmet Arman1, Ozer Soylu, Ahmet Yildirim

  • 1Departamento de Cardiologia, Faculdade de Engenharia, Universidade Marmara, Istambul, Turquia. aarman@eng.marmara.edu.tr

Arquivos Brasileiros De Cardiologia
|January 15, 2009
PubMed

Insights

The IL1 family gene polymorphisms showed no significant association with Coronary Artery Disease (CAD) in the Turkish population. However, the IL1RN 2/2 genotype may increase the risk of Single Vessel Disease (SVD).

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Immunology

Background:

  • Coronary Artery Disease (CAD) is an inflammatory condition linked to atherosclerosis.
  • Variations in cytokine genes, particularly the IL1 family, are implicated in atherosclerosis development.

Purpose of the Study:

  • To investigate the association between IL1 family gene polymorphisms (IL1RN VNTR, IL1B -511, and +3953) and CAD in the Turkish population.
  • To determine if specific genotypes or alleles correlate with CAD, Single Vessel Disease (SVD), or Multiple Vessel Disease (MVD).

Main Methods:

  • Genotyping of IL1RN and IL1B polymorphisms using polymerase chain reaction (PCR) and restriction digestion.
  • Analysis of 427 individuals, including 257 CAD patients (91 SVD, 166 MVD) and 170 controls.

Main Results:

  • No significant differences in IL1RN and IL1B genotype or allele frequencies were observed between CAD patients and controls, or between MVD patients and controls.
  • A significant association was found between the IL1RN 2/2 genotype and SVD compared to controls (P=0.016, OR=2.94).

Conclusions:

  • IL1RN and IL1B polymorphisms do not appear to be associated with overall CAD or MVD in the Turkish population.
  • The IL1RN 2/2 genotype may serve as a potential risk factor for SVD in this demographic.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...